This Program Project focuses on the role of CRF superfamily peptides and their binding proteins, receptors and modulators in the integration of endocrine, autonomic, behavioral and immune responses to stress.
The first aim of this Program is to characterize physical interacfions between CRF family ligands, their receptors and binding proteins and to define motifs required to activate downstream signaling events.
The second aim i s to explore the physiologic and pathophysiologic significance of these molecules at the cellular and system levels and to study the control of protein expression and secretion as well as modes of action. Addressing questions of a complex ligand/receptor system is facilitated by the availability of key scientific tools. This core application is therefore designed to provide transgenic mice, antibodies, and immunoassays necessary to conduct the integrated studies proposed by the individual Projects. Transgenic mice over expressing components of the CRF system, or null-mutant mice lacking one or more CRFRs and/or ligands, are essential for elucidating the physiologic roles of these ligand and receptors in normal development and in disease states. Detection and/or neutralization of gene products in vitro and in vivo are dependent on high affinity and high titer antibodies of appropriate specificity against CRF family peptides and their soluble binding proteins and membrane bound receptors. Measurement of factors modulated by the CRF receptor-ligand system, including the pituitary hormone ACTH, the adrenal steroid corticosterone, and the pancreatic hormones insulin and glucagon, are also required. This Core can provide transgenic mice, high quality antibodies and assay services that require highly trained personnel and specialized equipment which would otherwise be unavailable to individual projects due to high cost. The establishment of a Core permits reduced costs, improved quality control, efficiency, specialization of technical personnel, standardization of protocols and the dedication of equipment and space. Core B is jointly directed by Drs. K.-F. Lee (transgenic mice unit, 5% effort) and W. Vale (antibody production and assay services, 3% effort).
;Integrated studies proposed by this Program aim to investigate of the CRF signaling network and will lead to the development of new means of treating stress-related and other serious human disorders, including treatment of insulin insensitivity disorders. The success of this Program is critically dependent on support services, including transgenic mice, high quality antibodies, and immunoassays, provided by Core B.
|Roustit, Manon M; Vaughan, Joan M; Jamieson, Pauline M et al. (2014) Urocortin 3 activates AMPK and AKT pathways and enhances glucose disposal in rat skeletal muscle. J Endocrinol 223:143-54|
|Jappelli, Roberto; Perrin, Marilyn H; Lewis, Kathy A et al. (2014) Expression and functional characterization of membrane-integrated mammalian corticotropin releasing factor receptors 1 and 2 in Escherichia coli. PLoS One 9:e84013|
|van der Meulen, Talitha; Huising, Mark O (2014) Maturation of stem cell-derived beta-cells guided by the expression of urocortin 3. Rev Diabet Stud 11:115-32|
|Zorrilla, Eric P; Logrip, Marian L; Koob, George F (2014) Corticotropin releasing factor: a key role in the neurobiology of addiction. Front Neuroendocrinol 35:234-44|
|Rivier, Jean E; Rivier, Catherine L (2014) Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance. Front Neuroendocrinol 35:161-70|
|Benner, Christopher; van der Meulen, Talitha; Cacéres, Elena et al. (2014) The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression. BMC Genomics 15:620|
|Szabadfi, K; Kiss, P; Reglodi, D et al. (2014) Urocortin 2 treatment is protective in excitotoxic retinal degeneration. Acta Physiol Hung 101:67-76|
|Koob, George F; Buck, Cara L; Cohen, Ami et al. (2014) Addiction as a stress surfeit disorder. Neuropharmacology 76 Pt B:370-82|
|Logrip, Marian L; Zorrilla, Eric P (2014) Differential changes in amygdala and frontal cortex Pde10a expression during acute and protracted withdrawal. Front Integr Neurosci 8:30|
|Logrip, Marian L; Vendruscolo, Leandro F; Schlosburg, Joel E et al. (2014) Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats. Neuropsychopharmacology 39:1722-31|
Showing the most recent 10 out of 358 publications